Baricitinib a selective Janus kinase (JAK) inhibitors 1&2 have been recognized as a potential
therapeutic option in systemic lupus (SLE), also known Baricitinib, a JAK inhibitor, has
demonstrated efficacy and safety in the treatment of dermatitis and arthritis 1 ; however, no
JAK inhibitor studies have been conducted in lupus nephritis (LN) maintain remission to date.